Financhill
Sell
37

ARCT Quote, Financials, Valuation and Earnings

Last price:
$13.14
Seasonality move :
4.53%
Day range:
$13.25 - $13.80
52-week range:
$8.04 - $25.88
Dividend yield:
0%
P/E ratio:
8.50x
P/S ratio:
2.74x
P/B ratio:
1.54x
Volume:
257.9K
Avg. volume:
505.6K
1-year change:
-42.53%
Market cap:
$361M
Revenue:
$138.4M
EPS (TTM):
-$2.53

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ARCT
Arcturus Therapeutics Holdings
$18.7M -$0.87 -59.12% -44.53% $67.40
AIM
AIM ImmunoTech
-- -$0.09 -23.08% -53.85% $4.50
ARMP
Armata Pharmaceuticals
$1.4M -$0.39 -- -56% $9.00
CATX
Perspective Therapeutics
$170.4K -$0.29 -- -55.87% $14.1071
ELMD
Electromed
$16.4M -- 12.26% -- $33.50
PLX
Protalix BioTherapeutics
$13.5M -- 0.09% -- $14.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ARCT
Arcturus Therapeutics Holdings
$13.31 $67.40 $361M 8.50x $0.00 0% 2.74x
AIM
AIM ImmunoTech
$0.04 $4.50 $2.8M -- $0.00 0% 13.27x
ARMP
Armata Pharmaceuticals
$2.29 $9.00 $82.9M -- $0.00 0% 917.38x
CATX
Perspective Therapeutics
$4.0000 $14.1071 $296.9M -- $0.00 0% 28.19x
ELMD
Electromed
$19.30 $33.50 $161.9M 24.43x $0.00 0% 2.82x
PLX
Protalix BioTherapeutics
$1.42 $14.00 $113M 35.50x $0.00 0% 1.99x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ARCT
Arcturus Therapeutics Holdings
6.03% 2.197 5.22% 4.69x
AIM
AIM ImmunoTech
48.41% 0.745 17.25% 0.71x
ARMP
Armata Pharmaceuticals
-- 2.403 -- --
CATX
Perspective Therapeutics
-- 1.363 -- --
ELMD
Electromed
-- 2.259 -- 4.79x
PLX
Protalix BioTherapeutics
-- -1.225 -- 1.62x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ARCT
Arcturus Therapeutics Holdings
-- -$16.8M -26.76% -27.08% -66.04% -$35.3M
AIM
AIM ImmunoTech
$27K -$4.5M -219.06% -256.33% -9994.29% -$3.3M
ARMP
Armata Pharmaceuticals
-- -$8.2M -- -- -- -$7.7M
CATX
Perspective Therapeutics
-- -$21.8M -- -- -- -$26.2M
ELMD
Electromed
$12.2M $2.1M 16.57% 16.57% 13.65% $2.2M
PLX
Protalix BioTherapeutics
$1.9M -$4.1M 8.88% 10.9% -36.84% -$5.4M

Arcturus Therapeutics Holdings vs. Competitors

  • Which has Higher Returns ARCT or AIM?

    AIM ImmunoTech has a net margin of -55.25% compared to Arcturus Therapeutics Holdings's net margin of -10571.43%. Arcturus Therapeutics Holdings's return on equity of -27.08% beat AIM ImmunoTech's return on equity of -256.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARCT
    Arcturus Therapeutics Holdings
    -- -$0.52 $248.8M
    AIM
    AIM ImmunoTech
    77.14% -$0.06 $5.6M
  • What do Analysts Say About ARCT or AIM?

    Arcturus Therapeutics Holdings has a consensus price target of $67.40, signalling upside risk potential of 406.39%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Arcturus Therapeutics Holdings, analysts believe AIM ImmunoTech is more attractive than Arcturus Therapeutics Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARCT
    Arcturus Therapeutics Holdings
    8 0 0
    AIM
    AIM ImmunoTech
    1 0 0
  • Is ARCT or AIM More Risky?

    Arcturus Therapeutics Holdings has a beta of 2.273, which suggesting that the stock is 127.348% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.

  • Which is a Better Dividend Stock ARCT or AIM?

    Arcturus Therapeutics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARCT or AIM?

    Arcturus Therapeutics Holdings quarterly revenues are $25.5M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Arcturus Therapeutics Holdings's net income of -$14.1M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Arcturus Therapeutics Holdings's price-to-earnings ratio is 8.50x while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings is 2.74x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARCT
    Arcturus Therapeutics Holdings
    2.74x 8.50x $25.5M -$14.1M
    AIM
    AIM ImmunoTech
    13.27x -- $35K -$3.7M
  • Which has Higher Returns ARCT or ARMP?

    Armata Pharmaceuticals has a net margin of -55.25% compared to Arcturus Therapeutics Holdings's net margin of --. Arcturus Therapeutics Holdings's return on equity of -27.08% beat Armata Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ARCT
    Arcturus Therapeutics Holdings
    -- -$0.52 $248.8M
    ARMP
    Armata Pharmaceuticals
    -- -$0.20 --
  • What do Analysts Say About ARCT or ARMP?

    Arcturus Therapeutics Holdings has a consensus price target of $67.40, signalling upside risk potential of 406.39%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $9.00 which suggests that it could grow by 293.01%. Given that Arcturus Therapeutics Holdings has higher upside potential than Armata Pharmaceuticals, analysts believe Arcturus Therapeutics Holdings is more attractive than Armata Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARCT
    Arcturus Therapeutics Holdings
    8 0 0
    ARMP
    Armata Pharmaceuticals
    0 0 0
  • Is ARCT or ARMP More Risky?

    Arcturus Therapeutics Holdings has a beta of 2.273, which suggesting that the stock is 127.348% more volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.224%.

  • Which is a Better Dividend Stock ARCT or ARMP?

    Arcturus Therapeutics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARCT or ARMP?

    Arcturus Therapeutics Holdings quarterly revenues are $25.5M, which are larger than Armata Pharmaceuticals quarterly revenues of --. Arcturus Therapeutics Holdings's net income of -$14.1M is lower than Armata Pharmaceuticals's net income of -$6.5M. Notably, Arcturus Therapeutics Holdings's price-to-earnings ratio is 8.50x while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings is 2.74x versus 917.38x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARCT
    Arcturus Therapeutics Holdings
    2.74x 8.50x $25.5M -$14.1M
    ARMP
    Armata Pharmaceuticals
    917.38x -- -- -$6.5M
  • Which has Higher Returns ARCT or CATX?

    Perspective Therapeutics has a net margin of -55.25% compared to Arcturus Therapeutics Holdings's net margin of --. Arcturus Therapeutics Holdings's return on equity of -27.08% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ARCT
    Arcturus Therapeutics Holdings
    -- -$0.52 $248.8M
    CATX
    Perspective Therapeutics
    -- -$0.25 --
  • What do Analysts Say About ARCT or CATX?

    Arcturus Therapeutics Holdings has a consensus price target of $67.40, signalling upside risk potential of 406.39%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 252.68%. Given that Arcturus Therapeutics Holdings has higher upside potential than Perspective Therapeutics, analysts believe Arcturus Therapeutics Holdings is more attractive than Perspective Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARCT
    Arcturus Therapeutics Holdings
    8 0 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is ARCT or CATX More Risky?

    Arcturus Therapeutics Holdings has a beta of 2.273, which suggesting that the stock is 127.348% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.

  • Which is a Better Dividend Stock ARCT or CATX?

    Arcturus Therapeutics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARCT or CATX?

    Arcturus Therapeutics Holdings quarterly revenues are $25.5M, which are larger than Perspective Therapeutics quarterly revenues of --. Arcturus Therapeutics Holdings's net income of -$14.1M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, Arcturus Therapeutics Holdings's price-to-earnings ratio is 8.50x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings is 2.74x versus 28.19x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARCT
    Arcturus Therapeutics Holdings
    2.74x 8.50x $25.5M -$14.1M
    CATX
    Perspective Therapeutics
    28.19x -- -- -$18.2M
  • Which has Higher Returns ARCT or ELMD?

    Electromed has a net margin of -55.25% compared to Arcturus Therapeutics Holdings's net margin of 12.06%. Arcturus Therapeutics Holdings's return on equity of -27.08% beat Electromed's return on equity of 16.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARCT
    Arcturus Therapeutics Holdings
    -- -$0.52 $248.8M
    ELMD
    Electromed
    77.97% $0.21 $43.9M
  • What do Analysts Say About ARCT or ELMD?

    Arcturus Therapeutics Holdings has a consensus price target of $67.40, signalling upside risk potential of 406.39%. On the other hand Electromed has an analysts' consensus of $33.50 which suggests that it could grow by 73.58%. Given that Arcturus Therapeutics Holdings has higher upside potential than Electromed, analysts believe Arcturus Therapeutics Holdings is more attractive than Electromed.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARCT
    Arcturus Therapeutics Holdings
    8 0 0
    ELMD
    Electromed
    2 0 0
  • Is ARCT or ELMD More Risky?

    Arcturus Therapeutics Holdings has a beta of 2.273, which suggesting that the stock is 127.348% more volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

  • Which is a Better Dividend Stock ARCT or ELMD?

    Arcturus Therapeutics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARCT or ELMD?

    Arcturus Therapeutics Holdings quarterly revenues are $25.5M, which are larger than Electromed quarterly revenues of $15.7M. Arcturus Therapeutics Holdings's net income of -$14.1M is lower than Electromed's net income of $1.9M. Notably, Arcturus Therapeutics Holdings's price-to-earnings ratio is 8.50x while Electromed's PE ratio is 24.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings is 2.74x versus 2.82x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARCT
    Arcturus Therapeutics Holdings
    2.74x 8.50x $25.5M -$14.1M
    ELMD
    Electromed
    2.82x 24.43x $15.7M $1.9M
  • Which has Higher Returns ARCT or PLX?

    Protalix BioTherapeutics has a net margin of -55.25% compared to Arcturus Therapeutics Holdings's net margin of -35.79%. Arcturus Therapeutics Holdings's return on equity of -27.08% beat Protalix BioTherapeutics's return on equity of 10.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARCT
    Arcturus Therapeutics Holdings
    -- -$0.52 $248.8M
    PLX
    Protalix BioTherapeutics
    19.11% -$0.05 $45.2M
  • What do Analysts Say About ARCT or PLX?

    Arcturus Therapeutics Holdings has a consensus price target of $67.40, signalling upside risk potential of 406.39%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 885.92%. Given that Protalix BioTherapeutics has higher upside potential than Arcturus Therapeutics Holdings, analysts believe Protalix BioTherapeutics is more attractive than Arcturus Therapeutics Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARCT
    Arcturus Therapeutics Holdings
    8 0 0
    PLX
    Protalix BioTherapeutics
    0 0 0
  • Is ARCT or PLX More Risky?

    Arcturus Therapeutics Holdings has a beta of 2.273, which suggesting that the stock is 127.348% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.227, suggesting its less volatile than the S&P 500 by 122.694%.

  • Which is a Better Dividend Stock ARCT or PLX?

    Arcturus Therapeutics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARCT or PLX?

    Arcturus Therapeutics Holdings quarterly revenues are $25.5M, which are larger than Protalix BioTherapeutics quarterly revenues of $10.1M. Arcturus Therapeutics Holdings's net income of -$14.1M is lower than Protalix BioTherapeutics's net income of -$3.6M. Notably, Arcturus Therapeutics Holdings's price-to-earnings ratio is 8.50x while Protalix BioTherapeutics's PE ratio is 35.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings is 2.74x versus 1.99x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARCT
    Arcturus Therapeutics Holdings
    2.74x 8.50x $25.5M -$14.1M
    PLX
    Protalix BioTherapeutics
    1.99x 35.50x $10.1M -$3.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Can SharkNinja Stock Go?
How High Can SharkNinja Stock Go?

If you know popular consumer appliance brands Shark and Ninja,…

Will Oklo Stock Double?
Will Oklo Stock Double?

Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…

Why a $5 Stock Is Suddenly a Cash Machine
Why a $5 Stock Is Suddenly a Cash Machine

If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
42
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Alerts

Buy
77
VBTX alert for Jul 15

Veritex Holdings [VBTX] is down 3.26% over the past day.

Buy
72
MNPR alert for Jul 15

Monopar Therapeutics [MNPR] is down 8.6% over the past day.

Buy
56
NBIS alert for Jul 15

Nebius Group NV [NBIS] is up 2.98% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock